Laura holds a BA in Biology and Psychology from Harvard University, and a PhD in Neuroscience from MIT. Joey holds a Bachelor of Science in Finance from American University and is FINRA-certified in Series 7, Series 63 and Securities Industry Essentials. Michael's previous experience includes venture development at Health Wildcatters Seed Accelerator and product development in various roles at the Institute for Environmental and Exercise Medicine and as an Aerospace Medicine Clerk at NASA. Drew Biedermann is an Associate with the TechAtlas division of RA Capital Management. Her graduate research investigated inhibitors of influenza virus and characterizing hydrophobic polycationic antimicrobial surfaces. Prior to management consulting, Mr. Grau was Director of Marketing & Business Development at a clinical information technology startup. Merediths previous experience includes Medical Education Researcher and Medical Scribe positions at BMC Global Inc. and Longwood Pediatrics, respectively. Jon's primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Abhishek has a BS in Bioproducts and Biosystems Engineering and a BS in Chemistry from University of Minnesota, Twin Cities. Peter Kolchinsky Net Worth | Age, Height, Weight, Dating And More Peter Kolchinsky 285 Followers Scientist turned biotech investor, always learning, guided by fatherhood, share The Economist's world view, inspired to write by Hamilton's Federalist Papers. Prior to this, she served as Director, Talent Acquisition and Operations at Flagship Pioneering, a role in which she built talent systems to support the growth of 30+ pre-series B biotech startup companies. Anas primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Nate has a BS in Biological Sciences from University of Vermont. Previously, Jake covered solid tumor oncology landscapes. His responsibilities include managing the portfolios public equity positions, monitoring market, sector, and individual equity dynamics, and maintaining relationships with broker/dealer counterparties. Sadik Kassim is a scientist and executive with extensive experience in the biotechnology industry with a specific focus on cell and gene therapy bioprocessing and translational research. Christys primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Most of Joels career was spent as a medicinal chemist in pharma, where he capped a 28-year career at Bristol-Myers Squibb by spending the last five years as Vice President and Global Head of Discovery Chemistry, working across all therapeutic areas. In preparing the information contained in this website, RA Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Ross primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. He holds a BA in Neuroscience with a minor in Molecular and Cellular Biology from Colorado College. Lorena Chen is a Fund Controller at RA Capital Management. Phi previously worked as an Executive Assistant at Relay Therapeutics. Pieter previously worked as a consultant with McKinsey & Company, where he managed a variety of healthcare engagements, including pharmaceutical mergers, biotech product launch plans, OTC product rationalization, and hospital acquisitions. Kathryn holds a BA in Geography and Peace and Conflict Studies from Colgate University, a MSc in International Development: Environment and Development from the University of Manchester (UK), and a MA and Ph.D. in Geography from Clark University (2016). Senior Research Assistant, Venture Analytics. Erichs primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Prior to Catamaran, Mark served as Vice President, Legal Affairs at Rubius Therapeutics where he was responsible for leading internal legal activities in support of Rubius IPO and its growth to a clinical-stage company. James Schneider is the Deputy General Counsel at RA Capital Management. Jaimie holds a BA in Biology Boston College, with Minors in Medical Humanities and Sociology, and a Master of Public Health from Boston University School of Public Health. Mario has more than two decades of experience in vaccinology, virology and immunology in large pharma, government, academy, and biotech settings. Prior to Citigroup, he held various accounting and analyst roles at EY, Morgan Stanley, BBH, and Deloitte. Jaime is an Executive Assistant at RA Ventures (RAVen). Brendans primary responsibility is managing all aspects of the tax function. He holds BA and MA degrees in immunology from the University of Cambridge, an MD from University College London, and an MAS in clinical research from UCSF. Samuel Chowdhury is a Software Engineerat RA Capital Management. Soumya has contributed to over 75 drug discovery programs ranging from small startups to large pharma, leading to nine development candidates currently in various stages of clinical trials. Derek works on both public and private investments and serves as a Board Director for 89Bio, Achilles Therapeutics, iTeos Therapeutics, Connect Bio, CANbridge, andWerewolf Therapeutics. She has published over fifty papers in peer reviewed journals. in Life Science from National Taiwan University, M.S. After joining RA Ventures as Chief Development Officer, Ed built the development team, oversaw development of six compounds from discovery-stage through to clinical-stage, and led the formation of several new companies, including Lusaris Therapeutics. Brians primary responsibility at RA Capital is to conduct due diligence on biotechnology companies. She holds a BBA in Marketing from Loyola University Maryland. Kyle's primary responsibility at RA is to lead investments in private companies that are developing innovative solutions to address climate change and environmental sustainability. Peter Kolchinsky, Founder and Managing Director of RA Capital Management, L.P. and Founder of the nonprofit No Patient Left Behind, sits down with Liked by Peter Kolchinsky We need YOU to help. Candice Galvez is an Executive Assistant at RA Capital Management. Largest investment: 7.9 million shares of Vor Biopharma worth $142 million at the time of its IPO . From time to time we may post specific open positions, but more often we will create positions for the right people. He also served as member of the Product Advisory Board at Concert Pharmaceuticals and as an Advisor to Nimbus Therapeutics. Alyssa Larson is an Associate Director within the TechAtlas division at RA Capital Management. Alyssas primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Americas +1 212 318 2000. We owe a debt to the people who have mentored us, and we in turn have a responsibility to turn our hard won lessons into a solid foundation for our industry's emerging innovators and leaders.. She previously held roles as a Senior Business Analyst at Cambridge Associates and a Systems Analyst at Wellington Management Company. from Harvard College and an M.B.A. from Harvard Business School. Kathryn Spencer is an Executive Assistant at RA Capital Management. Prior to Mintz, Kate held a Paralegal role at Loughran & Corbett, Attorneys, Inc. Kate holds a Bachelor's Degree in Political Science from Bridgewater State University and is a certified Paralegal in Massachusetts. After graduation he got $4 Million from Vertex Pharma co-founder Rich Aldrich and started picking biotech stocks at RA. Emory Werner is an Associate with the TechAtlas division of RA Capital Management. Prior to MRL Ventures, Josh was a Venture Partner with Atlas Venture and a Partner at Prism Venture Partners, focusing on company formation and seed and Series A investing. Alex has a BA with a triple-major in Finance, Economics, and Math from UMass Lowell. Michael is chair of the Board of Managers of the Harvard Pilgrim Health Care Institute. Prior to RA, TJ was at KPMG where he was a Senior Audit Associate. MarketScreener: Created by Investors for Investors! Anurag holds a BSE in Biomedical Engineering and a BS in Economics from Duke University. Milind has more than 25 years of leadership and operational experience through all stages of drug discovery and development. Peter Kolchinsky - RA Capital Management - Insider Monkey Craig holds a BA in Political Science from Bridgewater State College and a JD from Boston College Law School. Prior to this role, Kate worked with the Venture team evaluating early stage investment opportunities and mapped a number of competitive landscapes, including ophthalmology, lower GI, and non-viral liver disease. Ernestos primary responsibility at RA Capital is to coordinate various technology related initiatives across the company and oversee their initiation, planning, and execution. Former Greenwich Selectman Peter Crumbine dies at age 84 Ding Sun is a Senior Software Engineer at RA Capital Management. Lorena has dual degrees from Beijing Foreign Studies University: a Bachelor of Business Administration in Accounting and a Bachelor of Arts in English Literature. Before entering the life science space, Kat held various accounting roles in the retail industry and started her career at Ernst & Young. He researched HIV at Harvard, where he earned his PhD, and then co-founded RA Capital Management, a Boston-based life-sciences investment firm focused on funding and creating companies developing new medicines. Alex has a BS in Chemistry and a Minor in Religious Studies from Davidson College. Prior to Flagship, Emily held roles as Associate Director, Head of Global Talent Acquisition and Associate Director, Recruiting Operations & Analytics at bluebird bio. BioVentures. Currently, Dr. Kolchinsky occupies the position of Chairman & Chief Executive Officer of Research Alliance Corp. II (which he founded in 2020) and Managing Partner at RA Capital Management LP (which he founded in 2004), Managing Partner at RA Capital Management LP (Private Equity) (which he founded) (a subsidiary of RA Capital Management LP). In this role he works closely with the RA Ventures team to evaluate and incubate early stage therapeutic programs. Prior to RAVen, Natalie served as an EA for three years at Massachusetts Technology Collaborative (MassTech), a Boston agency supporting business formation and growth in the state's technology sector. Sris primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Danielle received her PhD in Neuroscience from the Massachusetts Institute of Technology. Prior to moving to BMS, he spent five years at Hoffmann La-Roche as a research scientist. Patrick received his PhD in Natural Sciences, specifically Biochemistry and Molecular Biology, from the Leopold-Franzens University, Innsbruck, Austria. Previously, Nate covered atopic dermatitis, psoriasis, dermatology, colorectal cancer, cancer diagnostics, and broader tools and diagnostics as a Senior Associate within RAs TechAtlas division. Her primary responsibilities are to support our Venture Team by coordinating management agendas, calendars, and external events. He completed an internship in Internal Medicine and residency in Psychiatry at the University of Utah Health Sciences Center. Abhishek's primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. He worked previously at Global Prior Art, an intellectual property analysis firm, as a Partner and the Director of the Life Sciences Division. Milind has co-authored more than 80 scientific articles, is co-inventor on 30 patents, and is a frequent speaker at international scientific conferences. in Engineering Sciences in Bioengineering from Harvard University and a PhD in Medical Engineering and Medical Physics from the Harvard-MIT Health Sciences and Technology (HST) Program. Rebecca conducts due diligence on biotechnology companies at RA Capital. In his Venture role, Mario is focusing on early-stage investment and company creation. In these commercial roles, he initiated innovative discovery deal structures with venture companies, research foundations, and large integrated deals with pharmaceutical companies. As the first and founding member of Kymeras scientific team, Jesse was responsible for building the companys industry-leading targeted protein degradation platform and pipeline, and he helped secure the companys Series A and B financings as well as a partnership with Vertex. Christinas previous experience includes Stem Cell Program Manager at the Broad Institute and Deputy Editor at Cell Stem Cell. Vanderpump Rules' Peter Madrigal's Age. He holds a BS in Computer Science from Northeastern University. Mr. Grau earned his BA with High Honors from Davidson College, where he was awarded a Dana Honor Scholarship and elected to Phi Beta Kappa, and his MPhil, MA, and MAR degrees from Yale University, where he was awarded the Day Graduate Prize and was the recipient of a Mellon Fellowship in the Humanities. Michael is Executive Vice President at Capstan Therapeutics. Mark Boshar is a Venture Partner at RA Ventures (RAVen), focusing on new company creation. Laura has a BS in Human Services; Clinical Concentration and a Minor in Disabilities Studies from the University of Delaware. Tom has a BS in Physiological Sciences from University of California Los Angeles. He was also the co-founder and President of Research and Development of Cydan, a rare disease accelerator. Alonso was also a chemistry professor at the Universidad de los Andes in Colombia. James primary responsibilities are to advise RA Capital on public and private investments, coordinate with portfolio companies regarding deal structures and terms, and provide counsel and oversight on regulatory matters. April 28, 2023 9:39am. Prior to RA, Dan spent three years in Systems Engineer and Technical Consultant roles at Withum Smith + Brown, where he provided cloud and hybrid implementation guidance for clients within industries such as healthcare, construction, and fitness. Asthas primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. Maryann received her Bachelor of Science in English from Northeastern University. Vanderpump Rules: How Old Is Peter Madrigal? - Screen Rant As the Chief Scientific Officer at Mustang Bio, Sadik managed the foundational build-out of the companys preclinical and manufacturing activities. Gunes holds a BSc in Biological Sciences and Bioengineering from Sabanci University, a MSc in Molecular and Cellular Biology and a PhD in Biochemistry from the University of Heidelberg. No Patient Left Behind | Steering committee | Peter Kolchinsky Michael has a BS in Business Administration from Boston University with concentrations in Finance and Accounting. He holds a BA in History from University of Massachusetts, Amherst and a Master's of Urban Affairs from Boston University. Patrick was instrumental to building Constellations discovery platform, establishing a portfolio of competitive clinical candidates and drove the maturation of the companys development efforts, leading to one PhIII and two PhII assets and three additional clinical candidates. He is also active in the firms outreach efforts, speaking frequently both at industry events and in classrooms. Her doctoral research investigated the folding and aggregation of gamma-crystallins associated with cataract formation. Zach Scheiner is a Principal on the Investment Team at RA Capital Management. Erich holds a BA in English Literature and Language from Harvard University and a PhD in Microbiology from the University of North Carolina, Chapel Hill. Kriti Subramanyam is an Associate within the TechAtlas division of RA Capital Management. He also supports select RAVen portfolio companies in active strategic operating roles and serves as Board Director for GIVax, Summation Bio, and Astro Therapeutics. from Yale and practiced as a cardiac anesthesiologist. Prior to RA Capital, he represented emerging companies and venture capital investment funds at two international law firms. Sarah joined our team from MPM Capital where she served as the COO & General Counsel. Shannon's primary responsibilities are to manage the front desk and office facilities. Andrew Levin is a Partner and Managing Director on the Investment Team at RA Capital Management and spearheads a drug discovery effort that has led to the formation of several new companies. Lucas primary responsibilities are to advise on regulatory matters and assist in the development, implementation, and testing of the compliance program. Harvey holds an MS in Finance from Bentley University McCallum Graduate School of Business and a BS in Corporate Finance and Accounting from Bentley University. David holds a PhD from Harvard University in Biophysics and a BS in Molecular Biology from Texas A&M University. Toms primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Henry has a BA in Biology & Economics from Dartmouth College. Jess'sprimary responsibility is to direct a concerted effort to analyze, design, and shape internal and external narratives. Peter Kolchinsky is a father, scientist, investor, teacher, and author. Generali's No.3 investor Caltagirone withholds backing for 2022 accounts -sources, Musk says Tesla likely to launch full self-drive technology 'this year', Exclusive: JPMorgan employees gripe about Dimon's return-to-office edict, SpaceX rocket explosion illustrates Elon Musk's 'successful failure' formula, Cucinelli posts 33% rise in Q1 sales, confirms 2023 revenue growth forecast, Exclusive-Peter Thiel, Republican megadonor, won't fund candidates in 2024 - sources, Virginia Governor Youngkin 'humbled' by talk of possible presidential run, European Midday Briefing: Mood Brighter After -2-, Tim Cook unveils new Apple store in India, Morgan Stanley's dealmaking CEO Gorman signals more transactions to come, RA Capital Management LP (Private Equity). Daniel holds both a BS and MS degree in Microbiology and Immunology from McGill University. Previously, Danielle was an Associate at RA Capital, and worked in IP and tech licensing at Seven Bridges Genomics and the MIT Technology Licensing Office, respectively. Laura is an Executive Assistant at RA Capital Management. He holds a BS in Finance from Providence College. Daniel Bahcheli is an Associate Director at RA Capital Management. Garrett has worked cross-functionally across the landscape of in vivo and ex vivo genetic medicine modalities, often at the interface of payload design, platform research and manufacturing, IND-enabling activities, bioanalytical and computational biology, and strategy. Prior to her stint coaching, she received her BS in Psychology with a Minor in History from Union College in NY. Nadim Shohdy is an EIR at RA Capital. Tom has a BA in Business Administration from St. Anselm College and earned both his Chartered Financial Analyst and Chartered Alternative Investment Analyst designations. Previously in his career, he served as Associate General Counsel at Millennium Pharmaceuticals (now Takeda Oncology) where he built the legal department and led internal legal activities supporting several transformative pharmaceutical partnerships, a substantial global patent estate, and the companys IPO. Peter Kolchinsky graduated from Harvard with a Ph.D. in virology in 2001. Jessica holds a BA in Linguistics from Brigham Young University and a PhD in auditory neuroscience from the Division of Medical Sciences at Harvard University. Prior to Localytics, Matt served as software engineer at Mathworks. Kathryn previously held roles as Executive Assistant and Office Manager at Kojin Tx. Prior to RA Capital, Nate worked as an Investment Analyst at Wolfram Ventures. Josh is currently a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital. Prior to joining biotech/pharma, she was a specialist in the corporate finance team at McKinsey & Co, focused on corporate transactions. Bethany is a Senior Finance Associate at RA Capital Management. He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. His doctoral research focused on breast cancer metastasis. Ed has 30 years of experience in preclinical and clinical drug development, and in regulatory affairs for pharmaceutical and biotechnology companies. Prior to joining RA, Michael was Associate Vice President at Merck Research Labs. Anthony Arceci is a Senior Associate with the TechAtlas division of RA Capital Management. Peter Kolchinsky @PeterKolchinsky 2h So competition among vaccine innovators required collaboration to expand production and rewards were high enough to hire all capable people in the world to work on this. Prior to joining the team at Enara Sophie was a medical oncologist at Guys and St Thomas NHS Foundation Trust in London, UK (GSTT). Tweet With huge thanks to RA Capital's Alex Martinez-Forte and Jacqueline Rhuda for extensive data analysis. Her primary responsibilities are to support our Venture Team by coordinating management agendas, calendars, and external events. Chris Caliri is the Chief Information Officer at RA Capital Management. Matts primary responsibilities at RA Capital are to gather team input to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities, and to provide software training and coordinate with outside technology vendors. He received his doctorate in Organic Chemistry from Ohio University, and was a Fellow and Instructor in Department of Medicine, Boston University School of Medicine. She is a Clinical Reader at Kings College London with a laboratory working on translational adaptions to CAR T cell engineering to optimize clinical utility. Nothing contained on the website constitutes investment advice, and the views expressed should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company. As a founder and member of Constellations executive team Patrick materially contributed to several successful financing rounds and deals, including a crossover round, an IPO and the ultimate acqusition of the company. Prior to this, he was a Postdoctoral Fellow at NYU Medical School in the laboratory of Dr. Danny Reinberg, exploring the functional downstream consequences of changes to the histone posttranslational modification landscape on processes that require access to DNA, including the regulation of gene expression. Matthew works on both public and private investments and serves as a Board Director for Cerebral Therapeutics, DTx Pharma, Emergence Therapeutics, Forge Biologics, Jnana Therapeutics, and Kira Pharmaceuticals. Peter Kolchinsky, PhD '01, is a founder, Portfolio Manager, and Managing Director at RA Capital Management, LLC, a multi-stage investment manager dedicated to evidence-based investing in healthcare and life sciences. Before joining Rubius, Mark spent a decade launching, building or advising a portfolio of early-stage venture backed life-sciences companies, including Visterra, Living proof, Kala Pharmaceuticals, and Homology Medicines. Most importantly, this book describes concrete . Rye Lane to Peter Pan & Wendy: the seven best films to watch on TV this Chris has a BS in Neurobiology and Behavior from Cornell University and a MA in Journalism from New York University. Michael conducts due diligence on biotechnology companies at RA Capital. Cristinas primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Peter is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools and serves on the boards of publicly- and privately-held life science companies. Tess has a BA with a double major in Economics and Peace & Conflict studies from the University of Toronto, Canada. Tim was hired as the fourth employee at Proteon and built a team that brought an innovative biologic for blood vessel remodeling from pre-clinical through two Phase 3 clinical trials. Natalie brings to RAVen more than six years of Administrative experience. Before Energetic, she was Head of Carbon Strategic Partnerships at Indigo Ag, where she led external innovation focused on solutions that minimize or sequester agricultural GHG emissions and deliver additional environmental, social, and economic co-benefits. Gabes primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. He is also an active member of the Big Brothers of Massachusetts Bay program. Jesse earned his Ph.D. in Biological Chemistry from MIT and was a Harvard Origins Research Fellow. Michael Ryan is an EIR at RA Capital. By continuing, you accept the use of these cookies. Ryan has a BS in Business Administration with a concentration in Accounting and Sports Management from Isenberg School of Management at University of Massachusetts, Amherst. Ana holds an MPH in Epidemiology and Biostatistics from Boston University School of Public Health and a BA in Neuroscience from Boston University. Peter Kolchinsky His graduate research investigated the role of fimbria in Bordetella adherence and virulence. Adison previously held posts as an Administrative Assistant and Office Manager at Dyer Brown Architects and as an Executive Assistant to the Principal and Office Manager at bKL Architecture. Prior to joining RAVen, Kat was a Partner at van den Boom & Associates where she provided accounting and finance services including new company formation through IPO and public company accounting support, SOX compliance implementation, and financial modeling to several public and private life science companies. Benjamin Hicks is a Venture Operations Associate at RA Capital Management. Ross has a BS in Biochemistry from University of Oregon and a PhD in Pharmacology & Molecular Sciences from Johns Hopkins University. Peter Pan has long been a character that audiences have held up a critical lens to, as the premise of an eternal boy who recruits isolated children naturally brings up some questions the more a person thinks about it.
Zones Of Regulation Powerpoint For Teachers,
Match The Following Data With The Correct Histogram,
Government Jobs Burlington, Iowa,
Huntsville Area Association Of Realtors Fees,
What Happened To Duncan Hines Cake Mixes?,
Articles P